Case Studies

Challenge An established generics company looking to acquire the French rights of an existing product franchise needed to perform regulatory and clinical due diligence on the French dossier.

Challenge An established cancer immunotherapy company needed help with a business plan and valuation for a new company to be setup in collaboration with a major US cancer center

Challenge A well-capitalized European pharma company needed on-the-ground support with a search for late stage therapeutics, devices and diagnostics acquisition opportunities in the US. Alacrita was...

Challenge A rapidly growing European-headquartered specialty medtech company wanted to conduct a search for M&A opportunities in the interventional medicine arena.

Challenge Our client was nearing the completion of a pivotal Phase III trial with a novel antibody-based therapeutic. The product was designed to delay recurrence in cancer patients with minimum...

Challenge A leading immuno-oncology biotech company with a pipeline of novel, first-in-class clinical stage assets needed medical support for multiple clinical and medical affairs activities in...

Challenge: A US-based cancer vaccine company developing a peptide-based product was in clinical trials in its lead indication. Recent laboratory research had revealed the target antigens were also...

Challenge A university in a developing country wanted advice on best practice for IP protection and technology transfer. Alacrita was engaged to develop a plan for provision of these services.A...

Challenge A major public/private investor in a BRIC territory needed help with an investment strategy for building a nationwide radiopharmaceutical infrastructure and capacity in its home country....

Challenge A major nuclear physics research institute looking to build a capability in nuclear medicine needed support with its R&D plan. Alacrita was engaged to help craft a new R&D strategy.

Challenge: Anti-nerve growth factor inhibitors are a new class of powerful analgesics in clinical development. They were put on clinical development hold by the FDA in 2012 due to joint-related...

Challenge: The technology transfer function of a leading cancer research institute needed a development plan for a promising small molecule lead series against a novel anti-invasion/anti-metastasis...